Parsons CG

References (3)

Title : Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease - Parsons_2013_Neurotox.Res_24_358
Author(s) : Parsons CG , Danysz W , Dekundy A , Pulte I
Ref : Neurotox Res , 24 :358 , 2013
Abstract :
PubMedSearch : Parsons_2013_Neurotox.Res_24_358
PubMedID: 23657927

Title : Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease - Francis_2012_Expert.Rev.Neurother_12_1351
Author(s) : Francis PT , Parsons CG , Jones RW
Ref : Expert Rev Neurother , 12 :1351 , 2012
Abstract :
PubMedSearch : Francis_2012_Expert.Rev.Neurother_12_1351
PubMedID: 23234396

Title : Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors - Plazas_2007_Eur.J.Pharmacol_566_11
Author(s) : Plazas PV , Savino J , Kracun S , Gomez-Casati ME , Katz E , Parsons CG , Millar NS , Elgoyhen AB
Ref : European Journal of Pharmacology , 566 :11 , 2007
Abstract :
PubMedSearch : Plazas_2007_Eur.J.Pharmacol_566_11
PubMedID: 17466293